Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Consulting on Raw Material Qualification and Supply Chain for ATMPs in the EMEA Region

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Consulting on Raw Material Qualification and Supply Chain for ATMPs in the EMEA Region

CMC Consulting for ATMP Raw Material Qualification in EMEA

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence Accelerating Next-Generation Therapies.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Executive Summary

For Advanced Therapy Medicinal Product (ATMP) developers targeting European markets, establishing a robust raw material qualification program is a foundational requirement for successful Investigational Medicinal Product Dossier (IMPD) submissions. This involves rigorous characterization and documentation of all starting materials, including plasmid DNA, viral seed stocks, and ancillary reagents, to ensure product consistency, quality, and a clear line of sight for regulatory bodies like the MHRA. A proactive strategy mitigates manufacturing risks and accelerates the path to clinical evaluation, aligning with an 18-24 month timeline to IND or equivalent.

Frequently Asked Questions

    What are the key differences in raw material expectations between US and EMEA regulatory bodies for viral vectors?

    While both regions demand high standards, EMEA submissions often place a greater initial emphasis on detailed traceability and sourcing documentation for all ancillary materials used in the manufacturing process. A comprehensive risk assessment for adventitious agents, particularly for biologically-sourced materials, is a point of focus in IMPD filings.

    How does plasmid DNA quality impact AAV production for IMPD submissions?

    The quality of the starting plasmid DNA directly influences the purity, identity, and consistency of the final AAV vector product. Using well-characterized, high-quality grade plasmid minimizes process variability and reduces the risk of introducing impurities that could complicate toxicology assessments or elicit unwanted immune responses.

    What documentation is required for Master Cell Banks (MCB) and Working Cell Banks (WCB) in an ATMP dossier?

    A complete history and characterization package is required. This includes documentation of the cell line’s origin, genetic stability over passages, identity verification (e.g., STR profiling), and extensive testing for sterility and adventitious agents (viruses, mycoplasma). This package forms a core component of the CMC section of an IMPD.

Defining the Raw Material Control Strategy

The consistency of a viral vector therapeutic is directly tied to the quality of its starting materials. For programs targeting EMEA approvals, a well-defined control strategy for every raw material is a prerequisite for a valid IMPD submission. This extends beyond the active substance to include plasmids, cell banks, and all ancillary reagents that enter the manufacturing workflow.

Our approach, executed within a >100,000 sq ft GxP-compliant facility, focuses on building a comprehensive data package for each component. This includes:

  • Supplier qualification and auditing

  • Phase-appropriate material specifications

  • Incoming quality control (QC) testing

  • Full traceability from source to final product

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

Plasmid DNA and Viral Seed Stock Qualification

The quality of plasmid DNA used for transfection and the integrity of Master and Working Viral Banks are primary drivers of final product quality for AAV, lentivirus, and adenovirus vectors. A failure to properly characterize these assets introduces significant risk into the program.

We establish robust analytical methods to confirm the identity, purity, and integrity of these starting materials. This ensures that the genetic sequence is correct and that the material is free from contaminants that could compromise the manufacturing process or the final product’s biological profile.

Connecting Supply Chain to Regulatory Success

A defensible raw material program provides the foundation for the entire CMC data package. Generating unambiguous long-term safety data, such as confirming the absence of vector sequences in non-target tissues (PMID: 24010702), begins with impeccably sourced and qualified starting materials. This level of control is fundamental to building a compelling safety narrative for regulators.

Achieving high therapeutic expression with vectors like AAV8 (PMID: 14551134) is dependent on a consistent manufacturing process, which is only possible with consistent raw materials. Variability in plasmid quality or cell bank performance can directly impact vector yield and potency. Strategic CMC Guidance For Regulatory Success ensures these variables are controlled from the outset, providing a clear and defensible path toward MHRA and other European agency submissions.

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

Technical Visualization: ATMP Raw Material Qualification Pathway

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities